Fentanyl and Propofol

Phase 3Small molecule

JJiangsu Hengrui Pharmaceutical Co., Ltd.

Fentanyl and Propofol is one of 2 small molecule programs targeting Adverse Respiratory Events. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Adverse Respiratory EventsNot yet recruiting

Adverse Respiratory EventsPhase 3

Not yet recruiting

Competition

Competitive Landscape

1 competitor in Adverse Respiratory Events

#DrugCompanyPhaseTrials

Spravato

WWim Janssens

Approved

1 2

Fentanyl and Propofol

JJiangsu Hengrui Pharmaceutical Co., Ltd.

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

ApprovedNot yet recruiting

Adverse Respiratory Events

NCT07748884

Clinical

Trials by Indication[1]

Mechanical Ventilation1 trial

Comparison of Analgesic Effect and Prognosis of Butorphanol and Fentanyl in Patients With Mechanical Ventilation

Unknown status·JJiangsu Hengrui Pharmaceutical Co., Ltd.·Phase 4·NCT04315935·355 enrolled

Adverse Respiratory Events1 trial

A Comparative Study on the Incidence of Respiratory Adverse Events Between Esketamine Combined With Remazolam and Traditional Propofol in Pediatric Gastroscopy

Not yet recruiting·SSecond Affiliated Hospital of Wenzhou Medical University·Approved·NCT07748884·120 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Fentanyl and Propofol. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Fentanyl and Propofol compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Fentanyl and Propofol. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Jiangsu Hengrui Pharmaceutical Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: JJiangsu Hengrui Pharmaceutical Co., Ltd.

Fentanyl and Propofol

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

Mechanical Ventilation1 trial

Adverse Respiratory Events1 trial

References

Drug Info

Quick Facts

Related News